Raymond James & Associates Savara Inc Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding SVRA
# of Institutions
128Shares Held
158MCall Options Held
67.6KPut Options Held
29.4K-
Nea Management Company, LLC Timonium, MD24.5MShares$80.3 Million7.93% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$47.8 Million11.08% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$40.5 Million6.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.62MShares$28.3 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.16MShares$26.8 Million1.86% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $374M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.